ADARx Pharmaceuticals (ADRX):Â ADARx Sets Terms, Targets Up to $372m in IPO, AbbVie Alongside
DARx brings a late-stage siRNA pipeline, a major AbbVie investment and multiple shots on goal into a biotech IPO window that needs a strong debut.
103 Views
ADARx Pharmaceuticals (ADRX US): Synthetic Expert Call Transcript (17 Sep 2026)
Clinical Best-in-Class Potential: Onvuzosiran (ADX-324) demonstrates superior durability over late-stage competitor donidalorsen, with its 300 mg...
95 Views
TRex Bio (TRXB): Biotech Sector Remains Open as Lilly Backed Bio Sets Terms for IPO
TRex Bio brings a Treg-focused biotech platform to market with a Phase 1 lead asset, strong existing investors and Eli Lilly backing as biotech...
99 Views
U.S. IPO & Equity Capital Markets Brief 9/21/2026
Period: September 21-25, 2026. Two qualifying IPOs are scheduled to trade this week. Bamboo and ADARx represent approximately....
100 Views